The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives
Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver f...
Gespeichert in:
| Veröffentlicht in: | Chemistry & biodiversity 2023-02, Vol.20 (2), p.e202201029-n/a |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e202201029 |
| container_title | Chemistry & biodiversity |
| container_volume | 20 |
| creator | Sahu, Rakesh Goswami, Sourav Narahari Sastry, G. Rawal, Ravindra K. |
| description | Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases. |
| doi_str_mv | 10.1002/cbdv.202201029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2770118131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2770118131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3739-e16e0d6101c524b6c170bfae65ab234039f25d9f2f7f1e1f1119686831c383bf3</originalsourceid><addsrcrecordid>eNqFkc9PwyAYhonR-Pvq0ZB48bLJB1tbvGl1arJED9NrQ-lHxHRlQjvjfy91cyZevAD5eN4nhJeQE2BDYIxf6LJaDjnjnAHjcovsQwJ8AFnGtjfnlO-RgxDeIh_n2S7ZE0nKxFjyfdLMXpE-eVxi09olUtVUNI68WmDXWk2fXNvfqJo6Q9vITmq1dI2zVaC2odOY8TS33r-6YMMlzTvvY-DbM-nazkc7-rBA3evDEdkxqg54vN4PyfPkdpbfD6aPdw_51XSgRSrkACFBViXAQI_5qEw0pKw0CpOxKrkYMSENH1dxMakBBAMAMsmSTIAWmSiNOCTnK-_Cu_cOQ1vMbdBY16pB14WCpykDyEBARM_-oG-u8018XU-lUsoR55EarijtXQgeTbHwdq78ZwGs6Jso-iaKTRMxcLrWduUcqw3-8_URkCvgw9b4-Y-uyK9vXn7lX-tmlKk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2777999422</pqid></control><display><type>article</type><title>The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sahu, Rakesh ; Goswami, Sourav ; Narahari Sastry, G. ; Rawal, Ravindra K.</creator><creatorcontrib>Sahu, Rakesh ; Goswami, Sourav ; Narahari Sastry, G. ; Rawal, Ravindra K.</creatorcontrib><description>Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases.</description><identifier>ISSN: 1612-1872</identifier><identifier>EISSN: 1612-1880</identifier><identifier>DOI: 10.1002/cbdv.202201029</identifier><identifier>PMID: 36703592</identifier><language>eng</language><publisher>Switzerland: Wiley Subscription Services, Inc</publisher><subject>Apoptosis ; Cell differentiation ; Cirrhosis ; ECM ; Fatty liver ; Fibroblast growth factor 2 ; Fibrosis ; flavonoid ; Flavonoids ; Flavonoids - metabolism ; Growth factors ; Hepatitis ; HSCs ; Humans ; Inflammation ; Intercellular Signaling Peptides and Proteins - metabolism ; Liver ; Liver - metabolism ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - drug therapy ; Liver diseases ; MAP kinase ; Metabolic disorders ; NAFLD ; Non-alcoholic Fatty Liver Disease - drug therapy ; PDGF ; Platelet-derived growth factor ; Stellate cells ; Toxins ; Vascular endothelial growth factor ; Viruses</subject><ispartof>Chemistry & biodiversity, 2023-02, Vol.20 (2), p.e202201029-n/a</ispartof><rights>2023 Wiley‐VHCA AG, Zurich, Switzerland</rights><rights>2023 Wiley-VHCA AG, Zurich, Switzerland.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3739-e16e0d6101c524b6c170bfae65ab234039f25d9f2f7f1e1f1119686831c383bf3</citedby><cites>FETCH-LOGICAL-c3739-e16e0d6101c524b6c170bfae65ab234039f25d9f2f7f1e1f1119686831c383bf3</cites><orcidid>0000-0001-9035-3579</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcbdv.202201029$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcbdv.202201029$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36703592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahu, Rakesh</creatorcontrib><creatorcontrib>Goswami, Sourav</creatorcontrib><creatorcontrib>Narahari Sastry, G.</creatorcontrib><creatorcontrib>Rawal, Ravindra K.</creatorcontrib><title>The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives</title><title>Chemistry & biodiversity</title><addtitle>Chem Biodivers</addtitle><description>Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases.</description><subject>Apoptosis</subject><subject>Cell differentiation</subject><subject>Cirrhosis</subject><subject>ECM</subject><subject>Fatty liver</subject><subject>Fibroblast growth factor 2</subject><subject>Fibrosis</subject><subject>flavonoid</subject><subject>Flavonoids</subject><subject>Flavonoids - metabolism</subject><subject>Growth factors</subject><subject>Hepatitis</subject><subject>HSCs</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Intercellular Signaling Peptides and Proteins - metabolism</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver diseases</subject><subject>MAP kinase</subject><subject>Metabolic disorders</subject><subject>NAFLD</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>PDGF</subject><subject>Platelet-derived growth factor</subject><subject>Stellate cells</subject><subject>Toxins</subject><subject>Vascular endothelial growth factor</subject><subject>Viruses</subject><issn>1612-1872</issn><issn>1612-1880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9PwyAYhonR-Pvq0ZB48bLJB1tbvGl1arJED9NrQ-lHxHRlQjvjfy91cyZevAD5eN4nhJeQE2BDYIxf6LJaDjnjnAHjcovsQwJ8AFnGtjfnlO-RgxDeIh_n2S7ZE0nKxFjyfdLMXpE-eVxi09olUtVUNI68WmDXWk2fXNvfqJo6Q9vITmq1dI2zVaC2odOY8TS33r-6YMMlzTvvY-DbM-nazkc7-rBA3evDEdkxqg54vN4PyfPkdpbfD6aPdw_51XSgRSrkACFBViXAQI_5qEw0pKw0CpOxKrkYMSENH1dxMakBBAMAMsmSTIAWmSiNOCTnK-_Cu_cOQ1vMbdBY16pB14WCpykDyEBARM_-oG-u8018XU-lUsoR55EarijtXQgeTbHwdq78ZwGs6Jso-iaKTRMxcLrWduUcqw3-8_URkCvgw9b4-Y-uyK9vXn7lX-tmlKk</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Sahu, Rakesh</creator><creator>Goswami, Sourav</creator><creator>Narahari Sastry, G.</creator><creator>Rawal, Ravindra K.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9035-3579</orcidid></search><sort><creationdate>202302</creationdate><title>The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives</title><author>Sahu, Rakesh ; Goswami, Sourav ; Narahari Sastry, G. ; Rawal, Ravindra K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3739-e16e0d6101c524b6c170bfae65ab234039f25d9f2f7f1e1f1119686831c383bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Apoptosis</topic><topic>Cell differentiation</topic><topic>Cirrhosis</topic><topic>ECM</topic><topic>Fatty liver</topic><topic>Fibroblast growth factor 2</topic><topic>Fibrosis</topic><topic>flavonoid</topic><topic>Flavonoids</topic><topic>Flavonoids - metabolism</topic><topic>Growth factors</topic><topic>Hepatitis</topic><topic>HSCs</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Intercellular Signaling Peptides and Proteins - metabolism</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver diseases</topic><topic>MAP kinase</topic><topic>Metabolic disorders</topic><topic>NAFLD</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>PDGF</topic><topic>Platelet-derived growth factor</topic><topic>Stellate cells</topic><topic>Toxins</topic><topic>Vascular endothelial growth factor</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahu, Rakesh</creatorcontrib><creatorcontrib>Goswami, Sourav</creatorcontrib><creatorcontrib>Narahari Sastry, G.</creatorcontrib><creatorcontrib>Rawal, Ravindra K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chemistry & biodiversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahu, Rakesh</au><au>Goswami, Sourav</au><au>Narahari Sastry, G.</au><au>Rawal, Ravindra K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives</atitle><jtitle>Chemistry & biodiversity</jtitle><addtitle>Chem Biodivers</addtitle><date>2023-02</date><risdate>2023</risdate><volume>20</volume><issue>2</issue><spage>e202201029</spage><epage>n/a</epage><pages>e202201029-n/a</pages><issn>1612-1872</issn><eissn>1612-1880</eissn><abstract>Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases.</abstract><cop>Switzerland</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36703592</pmid><doi>10.1002/cbdv.202201029</doi><tpages>23</tpages><orcidid>https://orcid.org/0000-0001-9035-3579</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1612-1872 |
| ispartof | Chemistry & biodiversity, 2023-02, Vol.20 (2), p.e202201029-n/a |
| issn | 1612-1872 1612-1880 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2770118131 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Apoptosis Cell differentiation Cirrhosis ECM Fatty liver Fibroblast growth factor 2 Fibrosis flavonoid Flavonoids Flavonoids - metabolism Growth factors Hepatitis HSCs Humans Inflammation Intercellular Signaling Peptides and Proteins - metabolism Liver Liver - metabolism Liver cancer Liver cirrhosis Liver Cirrhosis - drug therapy Liver diseases MAP kinase Metabolic disorders NAFLD Non-alcoholic Fatty Liver Disease - drug therapy PDGF Platelet-derived growth factor Stellate cells Toxins Vascular endothelial growth factor Viruses |
| title | The Preventive and Therapeutic Potential of the Flavonoids in Liver Cirrhosis: Current and Future Perspectives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A08%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Preventive%20and%20Therapeutic%20Potential%20of%20the%20Flavonoids%20in%20Liver%20Cirrhosis:%20Current%20and%20Future%20Perspectives&rft.jtitle=Chemistry%20&%20biodiversity&rft.au=Sahu,%20Rakesh&rft.date=2023-02&rft.volume=20&rft.issue=2&rft.spage=e202201029&rft.epage=n/a&rft.pages=e202201029-n/a&rft.issn=1612-1872&rft.eissn=1612-1880&rft_id=info:doi/10.1002/cbdv.202201029&rft_dat=%3Cproquest_cross%3E2770118131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2777999422&rft_id=info:pmid/36703592&rfr_iscdi=true |